Long-term PFS from TIVO-3: Tivozanib (TIVO) versus sorafenib (SOR) in relapsed/refractory (R/R) advanced RCC.

被引：3

作者：

Atkins, Michael B.

Verzoni, Elena

Escudier, Bernard

McDermott, David F.

Hutson, Thomas E.

Pal, Sumanta K.

Porta, Camillo

Asnis-Alibozek, Aviva G.

Kasturi, Vijay

Rini, Brian I.

机构：

[1] Georgetown Lombardi Comprehens Canc Ctr, Washington, DC USA

[2] Fdn IRCCS Ist Nazl Tumori, Dept Med Oncol, Milan, Italy

[3] Gustave Roussy, Villejuif, France

[4] Harvard Canc Ctr, Dana Farber, Beth Israel Deaconess Med Ctr, Boston, MA USA

[5] Texas A&M Coll Med, Bryan, TX USA

[6] City Hope Natl Med Ctr, Comprehens Canc Ctr, Dept Med Oncol & Therapeut, Duarte, CA USA

[7] Univ Bari A Moro, Bari, Italy

[8] Policlin Consorziale Bari, Bari, Italy

[9] Aveo Oncol, Boston, MA USA

[10] Vanderbilt Ingram Canc Ctr, Nashville, TN USA

来源：

关键词：

D O I：

10.1200/JCO.2022.40.6_suppl.362

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

362

引用

页数：3